• Save
Rethink the Academic Talk - 2
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Rethink the Academic Talk - 2

  • 1,870 views
Uploaded on

I welcome your comments/suggestions! This presentation is not meant to be understood without the narrative - there is a lot of additional information the presenter would say verbally. I hope to......

I welcome your comments/suggestions! This presentation is not meant to be understood without the narrative - there is a lot of additional information the presenter would say verbally. I hope to show that academic presentations can be interesting, credible, and informative.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
  • Dear Marin,

    First of all, my compliments. You've done a very good job in both presentations.

    This comment values for both of your presentations.

    What I missed (maybe you told it verbally, anyway...):
    1 - Who are you?
    2 - What's the point? What am I going to learn?
    3 - A structured ending... 'a - You've learned that...', 'b - Thank you', 'c - Your name, email/phone'

    The design is very good in the whole. You chose a very clean layout, but, it seems to me that you had some trouble with slides like numbers 4, 5, 9. 11, 15 and 19. I think you could have found better ways to express the idea you wanted to convey with those slides.

    Keep up the good work!

    Best regards.
    Are you sure you want to
    Your message goes here
No Downloads

Views

Total Views
1,870
On Slideshare
1,869
From Embeds
1
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
1
Likes
2

Embeds 1

http://www.linkedin.com 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Pharmaceutical Pricing and Reimbursement Systems in EU Member States
  • 2. Overview of the talk
    • 1. Background
    • 2. Pricing
    • 3. Reimbursement
    • 4. Concluding remarks
  • 3. 1. Background
  • 4. Why is the pharmaceutical market uncertain? High cost of bringing drugs to market and high rates of failure Patent system confers monopoly rights What should be price of product? What is acceptable level of profit?
  • 5. What tradeoffs do EU payers make in coverage decisions? Industrial Policy Public Policy
  • 6. Industrial policy trade-off of jobs and economic growth.
  • 7. Public policy trade-off of access, efficiency, and equity
  • 8. 2. Pricing
  • 9. The three main approaches to pricing are: free pricing, direct price controls, and indirect price controls
  • 10. Under free pricing manufacturers can price according to what the market will bear.
  • 11. Direct price controls force manufacturers to price at levels approved by the health system. negotiated prices cost-plus pricing international price comparisons
  • 12. Negotiated prices are set in negotiations between the manufacturer and the government and based on a variety of factors.
  • 13. Cost-plus pricing is set by the cost of manufacturing a drug plus an additional percentage profit level.
  • 14. Countries Lowest Original Country Lowest in EU In international price comparisons , prices are based on a weighted average of prices from a basket of countries.
  • 15. Indirect price controls incentivize manufacturers to keep prices within “acceptable” levels. reference pricing rate-of-return regulation
  • 16. Reference pricing sets a base price at which patients must pay out-of-pocket for excess costs above this price
  • 17. Rate-of-return regulation The UK allows certain manufacturers to freely price drugs within profit limits
  • 18. 3. Reimbursement
  • 19. The two main approaches to reimbursement are: listing and economic evaluation.
  • 20. Positive (negative) lists include (exclude) medicines for reimbursement.
  • 21. Health economic evaluation , which weighs costs against benefits of treatments, now plays a greater role in reimbursement.
  • 22. 4. Concluding remarks
  • 23. 27 different pricing and reimbursement policies in the EU
  • 24. Divergence in national pharmaceutical policies, but a trend toward health economic evaluation in coverage decisions
  • 25. Photo credits
    • Slide 7: padlock, http://www.sxc.hu/browse.phtml?f=view&id=204785
    • Slide 9: price tag, http://www.sxc.hu/photo/480217
    • Slide 12: handshake, http://www.sxc.hu/browse.phtml?f=view&id=1065245
    • Slide 16: building blocks, http://www.sxc.hu/photo/596909
    • Slide 19: money exchange, http://www.sxc.hu/photo/577717
    • Slide 20: pen, http:// www.sxc.hu/browse.phtml?f = view&id =921719
    • Slide 23: pharmaceuticals, http://www.sxc.hu/browse.phtml?f=view&id=1028441
    • Slide 24: pharmaceuticals, http://www.sxc.hu/photo/851433